Document is current
Any future updates will be listed below
-
Authors
Hamamoto, Yoshiyuki
Oura, Tomonori https://orcid.org/0000-0003-0872-8576
Hirase, Tetsuaki https://orcid.org/0000-0003-1691-8003
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03861052 at ClinicalTrials.govDocuments that mention this clinical trial
Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial
https://doi.org/10.1007/s13300-023-01485-3
Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis
https://doi.org/10.1007/s13300-025-01704-z
Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis
https://doi.org/10.1007/s13300-024-01534-5
Association Between Early Weight Loss and Metabolic Outcomes with Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J Post Hoc Analysis
https://doi.org/10.1007/s13300-025-01775-y
-
Funding
Funding for this research was provided by:
Eli Lilly Japan
Mitsubishi Tanabe Pharma Corporation
- License Information
-
More Information
Article History
Received: 19 October 2024
Accepted: 3 February 2025
First Online: 14 February 2025
Declarations
:
: All authors declare funding support for this study and manuscript from Eli Lilly Japan K.K. and Mitsubishi Tanabe Pharma Corporation. Yoshiyuki Hamamoto reports grants from Nippon Boehringer Ingelheim and speaker bureau fees from Eli Lilly Japan, Mitsubishi Tanabe Pharma Corporation, Sumitomo Pharma, Novo Nordisk Pharma, MSD, and Taisho Pharmaceutical. Dr. Hamamoto is an editorial advisory board member of Diabetes Therapy. To minimize bias, Dr. Hamamoto was excluded from all editorial decision-making related to the acceptance of this article for publication. Tomonori Oura and Tetsuaki Hirase are employees of Eli Lilly Japan and minor shareholders of Eli Lilly and Company.
: The study protocol was approved by independent ethical review boards at each study site (full list in Supplementary Table ). The study was conducted in accordance with the Declaration of Helsinki in 1964 (and its later amendments) and the Council for International Organizations of Medical Sciences International Ethical Guidelines. Participants were required to provide written informed consent prior to participating in the trial.
